Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Caribou Biosciences Inc

Healthcare US CRBU

1.595USD
-0.065(3.92%)

Last update at 2026-06-12T20:26:00Z

Day Range

1.591.77
LowHigh

52 Week Range

0.733.54
LowHigh

Fundamentals

  • Previous Close 1.66
  • Market Cap217.43M
  • Volume2292089
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-130.27300M
  • Revenue TTM11.16M
  • Revenue Per Share TTM0.12
  • Gross Profit TTM -96.36400M
  • Diluted EPS TTM-1.59

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -148.67500M -149.11400M -101.87700M -99.35100M -66.60200M
Minority interest - - - - -
Net income -148.12500M -149.10500M -102.07000M -99.42100M -66.92300M
Selling general administrative 37.91M 46.46M 38.46M 38.02M 24.32M
Selling and marketing expenses - - 3.52M - -
Gross profit 7.51M 6.07M 30.95M 13.85M 9.60M
Reconciled depreciation 3.65M 3.93M 3.29M 1.62M 0.98M
Ebit -136.19400M -166.61600M -116.05900M -106.39900M -66.97900M
Ebitda -132.54900M -162.68900M -112.53400M -106.26600M -68.17800M
Depreciation and amortization 3.65M 3.93M 3.52M 0.13M -1.19900M
Non operating income net other - - - 7.05M 0.25M
Operating income -136.19400M -166.61600M -116.05900M -106.39900M -66.97900M
Other operating expenses 147.35M 176.61M 150.54M 120.25M 76.58M
Interest expense - - - 8.54M 0.00800M
Tax provision -0.55000M -0.00900M 0.19M 0.07M 0.32M
Interest income - - - - 0.15M
Net interest income - - - - 0.14M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.55000M -0.00900M 0.19M 0.07M 0.32M
Total revenue 11.16M 9.99M 34.48M 13.85M 9.60M
Total operating expenses 143.71M 172.68M 147.01M 120.25M 76.58M
Cost of revenue 3.65M 3.93M 3.52M - -
Total other income expense net -12.48100M 17.50M 14.18M 7.05M 0.38M
Discontinued operations - - - - -
Net income from continuing ops -148.12500M -149.10500M -94.55400M -99.42100M -66.92300M
Net income applicable to common shares - - - -99.42100M -66.92300M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 175.37M 313.31M 440.97M 373.76M 442.36M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.91M 6.59M 6.16M 1.12M 0.67M
Total liab 53.19M 60.36M 72.57M 72.89M 54.53M
Total stockholder equity 122.17M 252.95M 368.40M 300.87M 387.82M
Deferred long term liab - - - - 24.61M
Other current liab 16.54M 23.62M 20.76M 16.08M 0.79M
Common stock 0.00900M 0.00900M 0.00800M 0.00600M 0.00600M
Capital stock 0.00900M 0.00900M 0.00800M 0.00600M 0.00600M
Retained earnings -596.51500M -448.39000M -299.28500M -197.21500M -97.79400M
Other liab - - - 17.99M 28.70M
Good will - - - - -
Other assets - - - 1.54M 0.97M
Cash 12.36M 16.29M 51.16M 58.34M 240.42M
Cash and equivalents - - - - -
Total current liabilities 25.41M 30.65M 28.30M 28.13M 25.83M
Current deferred revenue 1.90M 3.13M 2.85M 9.94M 8.70M
Net debt 14.87M 10.19M -23.67700M -30.59200M -240.42000M
Short term debt 1.20M 1.43M 1.58M 0.97M 12.35M
Short long term debt - - - - -
Short long term debt total 27.23M 26.49M 27.48M 27.75M -
Other stockholder equity 718.58M 701.08M 667.65M 499.60M 43.39M
Property plant equipment - - - 10.68M 4.89M
Total current assets 145.23M 219.38M 338.84M 260.25M 391.19M
Long term investments 3.50M 49.12M 51.33M 77.07M 45.30M
Net tangible assets - - - 300.87M 387.82M
Short term investments 126.98M 193.24M 277.67M 189.32M 135.41M
Net receivables 2.98M 3.25M 3.86M 4.66M 8.12M
Long term debt - - - - -
Inventory - - - -62.57100M -31.11100M
Accounts payable 5.78M 2.48M 3.12M 1.15M 3.99M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.10M 0.26M 0.03M -1.51800M -0.13500M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00600M 0.00600M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -197.21500M -97.79400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.15M 5.52M 1.59M 1.54M 0.97M
Deferred long term asset charges - - - - -
Non current assets total 30.14M 93.94M 102.13M 113.52M 51.16M
Capital lease obligations 27.23M 26.49M 27.11M 27.75M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 103.60M 86.61M -35.53900M -86.19500M -173.27600M
Change to liabilities - - - -0.78300M 34.90M
Total cashflows from investing activities 102.24M 86.61M -68.18300M -93.24900M -176.39700M
Net borrowings - - - - 1.03M
Total cash from financing activities 4.82M 16.72M 154.30M 2.13M 433.43M
Change to operating activities - - - 3.26M -0.86700M
Net income -148.12500M -149.10500M -102.07000M -99.42100M -66.92300M
Change in cash -3.93300M -34.86900M -7.17600M -182.08200M 224.51M
Begin period cash flow 16.34M 51.21M 58.38M 240.47M 15.95M
End period cash flow 12.41M 16.34M 51.21M 58.38M 240.47M
Total cash from operating activities -110.99200M -138.20000M -93.29100M -90.96600M -32.51900M
Issuance of capital stock 4.07M 15.19M 152.83M 0.00000M 429.85M
Depreciation 3.65M 3.93M 3.52M 1.62M 0.98M
Other cashflows from investing activities 1.14M -1.61200M - -0.60000M -1.00000M
Dividends paid - - - - -
Change to inventory - - - - -2.20000M
Change to account receivables 0.27M 0.61M 0.81M 0.95M -1.00300M
Sale purchase of stock - - - - 432.40M
Other cashflows from financing activities - 1.53M 1.58M -93.24900M 112.53M
Change to netincome - - - 11.72M 1.88M
Capital expenditures 1.36M 6.50M 11.61M 7.05M 3.12M
Change receivables - - - 4.22M -2.80300M
Cash flows other operating - - - -7.52200M -0.59900M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -182.08200M 224.51M
Change in working capital -0.48400M -5.11400M -7.31800M -4.20400M 29.07M
Stock based compensation 12.68M 16.71M 13.75M 11.72M 3.45M
Other non cash items 21.84M -4.61400M -1.17800M -0.58400M 2.43M
Free cash flow -112.35100M -144.70500M -104.90400M -98.02000M -35.64000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRBU
Caribou Biosciences Inc		 -0.065 3.92% 1.59 - - 19.49 1.78 9.39 -36.9426
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.99 4.74% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Caribou Biosciences Inc

2929 7th Street, Berkeley, CA, United States, 94710

Key Executives

Name Title Year Born
Dr. Steven B. Kanner Chief Scientific Officer 1959
Dr. Rachel E. Haurwitz Ph.D. Co-Founder, CEO, Pres & Director 1986
Mr. Jason V. O'Byrne M.B.A. Chief Financial Officer 1969
Ms. Barbara G. McClung Esq., J.D. Chief Legal Officer & Corp. Sec. 1955
Mr. Daniel Poon VP of Operations & Information Technology NA
Dr. Justin Skoble VP of Technical Operations NA
Ms. Amy Figueroa C.F.A. VP of Investor Relations & Corp. Communications NA
Ms. Cindy Hayashi VP of HR NA
Ms. Ruhi A. Khan M.B.A. Chief Bus. Officer 1975
Dr. Syed Ali-aamir Rizvi M.D. Chief Medical Officer 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.